Anacor to Present Clinical and Preclinical Data on Topical Anti-Inflammatory and Anti-Fungal Candidates, AN2728, AN2898 and AN2718, at the American Academy of Dermatology Annual Meeting
PALO ALTO, Calif.--(BUSINESS WIRE)--Mar 2, 2009 - Anacor Pharmaceuticals announced today that it will present six posters on topical anti-inflammatory and anti-fungal candidates, AN2728, AN2898 and AN2718, at the upcoming American Academy of Dermatology Annual Meeting, taking place March 6-10, 2009 in San Francisco, California.
AN2728 – Psoriasis and Atopic Dermatitis:
AN2898 – Psoriasis and Atopic Dermatitis:
AN2718 – Skin and Nail Fungal Infection:
About Anacor Pharmaceuticals
Anacor is a biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform. Anacor has focused initially on developing topical applications of its compounds to treat fungal, bacterial and inflammatory diseases. In addition, the Company is developing systemic antiviral and antibacterial therapeutics under a research and development agreement with GlaxoSmithKline. Anacor's most advanced product candidate is AN2690, a novel topical antifungal in development for the treatment of toenail onychomycosis, which is a fungal infection of the nail and nail bed. AN2690 is licensed to Schering-Plough Corporation under a worldwide development and commercialization agreement for all indications including the treatment of onychomycosis. For more information visit www.anacor.com.
This press release contains forward-looking statements, including statements regarding the progress of our clinical trials and the safety and efficacy of our product candidates. These statements relate to future events and involve known and unknown risks, uncertainties and other factors that could cause actual levels of activity, performance or achievement to differ materially from those expressed or implied by these forward-looking statements. Some factors that may affect these forward-looking statements include, but are not limited to, delays in the completion of our clinical trials, clinical failure at later stages of development and undesirable effects from our product candidates. These statements reflect the views of Anacor as of the date of this press release with respect to future events and, except as required by law, it undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this press release.
Contact: Anacor Pharmaceuticals
Anne Bowdidge, 650-543-7575
Posted: March 2009